Clinical trial Checkmate 142
CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial closed for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | BMS - Bristol Myers Squibb int. |
| EudraCT Identifier | 2013-003939-30 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02060188 |
| Inclusion criteria | metastatic RECIST 1.1 |
| Last update |